Albenatide

Drug Profile

Albenatide

Alternative Names: CJC-1134; CJC-1134-PC; PC-DAC™:Exendin-4

Latest Information Update: 10 Feb 2016

Price : $50

At a glance

  • Originator ConjuChem Biotechnologies
  • Developer ConjuChem; Kaijiejian Biopharmaceutical
  • Class Albumins; Antihyperglycaemics; Peptides; Small molecules; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 26 Mar 2015 Albenatide is still in phase II trials for Type-2 diabetes mellitus in USA and Canada (ConjuChem, pipeline, March 2015)
  • 15 Sep 2011 Phase-II clinical trials in Type-2 diabetes mellitus in USA (SC)
  • 15 Sep 2011 ConjuChem initiates enrolment in a Phase-II trial for Type 2 diabetes mellitus in Canada (NCT01514149)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top